Monsma F J, Shen Y, Ward R P, Hamblin M W, Sibley D R
Molecular Neuropharmacology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892.
Mol Pharmacol. 1993 Mar;43(3):320-7.
We have used the polymerase chain reaction technique to selectively amplify a guanine nucleotide-binding protein-coupled receptor cDNA sequence from rat striatal mRNA that exhibits high homology to previously cloned serotonin receptors. Sequencing of a full length clone isolated from a rat striatal cDNA library revealed an open reading frame of 1311 base pairs, encoding a 437-residue protein with seven hydrophobic regions. Within these hydrophobic regions, this receptor was found to be 41-36% identical to the following serotonin [5-hydroxytryptamine (5-HT)] receptors: 5-HT2 > 5-HT1D > 5-HT1C > 5-HT1B > 5-HT1A > 5-HT1E. Northern blots revealed a approximately 4.2-kilobase transcript localized in various brain regions, with the following rank order of abundance: striatum >> olfactory tubercle > cerebral cortex > hippocampus. Expression of this clone in COS-7 cells resulted in the appearance of high affinity, saturable binding of (+)-[2-125I] iodolysergic acid diethylamide ([125I]LSD) with a Kd of 1.26 nM. Among endogenous biogenic amines, only 5-HT completely inhibited [125I]LSD binding (Ki = 150 nM). The inhibition of [125I]LSD binding by other serotonergic agonists and antagonists revealed a pharmacological profile that does not correlate with that of any previously described serotonin receptor subtype. In addition, this receptor exhibits high affinity for a number of tricyclic antipsychotic and antidepressant drugs, including clozapine, amoxipine, and amitriptyline. In HEK-293 cells stably transfected with this receptor, serotonin elicits a potent stimulation of adenylyl cyclase activity, which is blocked by antipsychotic and antidepressant drugs. The distinct structural and pharmacological properties of this receptor site indicate that it represents a completely novel subtype of serotonin receptor. Based on its affinity for tricyclic psychotropic drugs and its localization to limbic and cortical regions of the brain, it is likely that this receptor may play a role in several neuropsychiatric disorders that involve serotonergic systems.
我们运用聚合酶链反应技术,从大鼠纹状体信使核糖核酸(mRNA)中选择性扩增出一种鸟嘌呤核苷酸结合蛋白偶联受体的互补脱氧核糖核酸(cDNA)序列,该序列与先前克隆的血清素受体具有高度同源性。对从大鼠纹状体cDNA文库中分离出的一个全长克隆进行测序,结果显示其开放阅读框为1311个碱基对,编码一个含有437个氨基酸残基且具有七个疏水区域的蛋白质。在这些疏水区域内,发现该受体与以下血清素[5-羟色胺(5-HT)]受体的同源性为41%-36%:5-HT2>5-HT1D>5-HT1C>5-HT1B>5-HT1A>5-HT1E。Northern印迹分析显示,一种约4.2千碱基的转录本定位于大脑的各个区域,丰度顺序如下:纹状体>>嗅结节>大脑皮层>海马体。该克隆在COS-7细胞中的表达导致出现了对(+)-[2-125I]碘麦角酸二乙酰胺([125I]LSD)的高亲和力、可饱和结合,解离常数(Kd)为1.26纳摩尔。在内源性生物胺中,只有5-HT能完全抑制[125I]LSD的结合(抑制常数Ki = 150纳摩尔)。其他血清素能激动剂和拮抗剂对[125I]LSD结合的抑制作用显示出一种药理学特征,该特征与任何先前描述的血清素受体亚型均不相关。此外,该受体对多种三环类抗精神病药物和抗抑郁药物具有高亲和力,包括氯氮平、阿莫沙平及阿米替林。在稳定转染了该受体的HEK-293细胞中,血清素能有效刺激腺苷酸环化酶的活性,而这种刺激会被抗精神病药物和抗抑郁药物阻断。该受体位点独特的结构和药理学特性表明它代表了一种全新的血清素受体亚型。基于其对三环类精神药物的亲和力以及在大脑边缘和皮质区域的定位,这种受体很可能在涉及血清素能系统的多种神经精神疾病中发挥作用。